Malignant Glioma Subset from Actuate 1801: A Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK-3b) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors.

Bruno Bastos

Malignant Glioma Subset from Actuate 1801: A Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK-3b) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors.

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
State	Published - 2021

Disciplines

Medicine and Health Sciences

Cite this

Malignant Glioma Subset from Actuate 1801: A Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK-3b) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors. / Bastos, Bruno.
In: Journal of Clinical Oncology, 2021.

Research output: Contribution to journal › Article › peer-review

@article{6f745ddc9d9944359f3eb2f68cd0ee81,

title = "Malignant Glioma Subset from Actuate 1801: A Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK-3b) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors.",

author = "Bruno Bastos",

year = "2021",

language = "American English",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Malignant Glioma Subset from Actuate 1801: A Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK-3b) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors.

AU - Bastos, Bruno

PY - 2021

Y1 - 2021

M3 - Article

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -